Loading...
•
Sep 30, 2023
Vaxart Q3 2023 Earnings Report
Vaxart's topline data from two Phase 2 trials of norovirus program was released and the company ended the quarter with $53.0 million in cash, cash equivalents, restricted cash and marketable securities.
Key Takeaways
Vaxart announced its Q3 2023 financial results, highlighting topline data from Phase 2 trials of its norovirus program. The company's monovalent norovirus candidate showed potential in reducing norovirus infection, acute gastroenteritis, and viral shedding. Vaxart ended the quarter with $53.0 million in cash, cash equivalents, restricted cash and marketable securities, anticipating cash runway into Q3 2024.
Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding
Clinical proof of concept for the Company's oral pill vaccine platform now established in two human challenge studies for norovirus and influenza
Vaxart ended the third quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $53.0 million
General and administrative expenses were $4.9 million for the third quarter of 2023
Forward Guidance
Vaxart anticipates it has cash runway into the third quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...